Clinical investigation of the expression of TSHR and BRAFV600E gene mutation in papillary thyroid carcinoma

doi:10.3877/cma.j.issn.1674-3946.2018.06.007

Chinese Journal of Operative Procedures of General Surgery(Electronic Edition) ›› 2018, Vol. 12 ›› Issue (06): 468-471. doi: 10.3877/cma.j.issn.1674-3946.2018.06.007

Special Issue: ；

• Original Article • Previous Articles Next Articles

Clinical investigation of the expression of TSHR and BRAFV600E gene mutation in papillary thyroid carcinoma

Shaolong Hao¹, Jihong Ma², Xincheng Liu³, Huanjie Chen³, Haitao Zheng³^,^†(), Xicheng Song⁴^,^†()

^1. Department of General Surgery, Beijing Luhe Hospital, Capital Medical University, Beijing
^2. Department of General medicine, Beijing Luhe Hospital, Capital Medical University, Beijing
^3. Department of Thyroid Surgery, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Shandong 264000, China
^4. Department of Otorhinolaryngology-Head & Neck Surgery, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Shandong 264000, China

Received:2017-06-26 Online:2018-12-26 Published:2018-12-26
Contact: Haitao Zheng, Xicheng Song
About author:
Corresponding author: Zheng Haitao, Email: zhenghaitao1972@126.com
Song Xicheng, Email: songxicheng@126.com
Supported by:
Natural Science Fundation of Shandong Province(ZR2015HL092); Key Research Project of Shandong Province(2015GSF118090); Municipal Scientific and Technological Development Project of Yantai city(2015YT06000060)

Abstract

Abstract:

Objective

To explore the relationship between expression of TSHR, TSHR-mRNA and BRAF^V600E gene mutation in papillary thyroid cancer.

Method

A total of 122 patients with papillary thyroid cancer were enrolled in this study. PCR was applied to detect gene mutation of BRAF^V600E in papillary thyroid cancers. All the patients were divided into BRAF^V600E gene mutation group and BRAF^V600E gene wild-type group. Immunohistochemical assay were used to detect expression of TSHR in papillary thyroid cancers. Western blotting and Real-time quantitative PCR (RT-PCR) were used to verify the results. Statistical analysis was performed by using SPSS17.0 software. Chi-squared test and Independent sample t test were applied to analyze the relationship between the expressions of TSHR, TSHR-mRNA and BRAF^V600E gene mutation. A P value <0.05 was considered as statistical significance.

Result

The expression levels of TSHR and TSHR-mRNA in papillary thyroid cancers was significant decreased (P<0.05), and the expression of TSHR and TSHR-mRNA in papillary thyroid cancers were decreased more obviously in BRAF^V600E gene mutation group than those in BRAF^V600E gene wild-type group.

Conclusion

BRAF^V600E gene mutation is associated with the lower expression of TSHR in papillary thyroid cancers.

Key words: Thyroid Neoplasms, Carcinoma, Papillary, Receptors, Thyrotropin

Shaolong Hao, Jihong Ma, Xincheng Liu, Huanjie Chen, Haitao Zheng, Xicheng Song. Clinical investigation of the expression of TSHR and BRAFV600E gene mutation in papillary thyroid carcinoma[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2018, 12(06): 468-471.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2018.06.007

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2018/V12/I06/468

Figures/Tables 6

References 11

[1]	Schneider DF, Chen H. New developments in the diagnosis and treatment of thyroid cancer [J]．CA: a cancer journal for clinicians, 2013, 63(6): 374-394.
[2]	Davies L, welch HG. Current Thyroid cancer trends in the United States [J]. JAMA Otolaryngol Head Neck Surg, 2014, 140(4): 317-322.
[3]	Garnett MJ, Marais R. Guilty as charged: BRAF is a human oncogene [J]. Cancer Cell.2004, 6(4):313-319.
[4]	Min HS, Lee C, Jung KC. Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population [J]. J Korean Med Sci, 2013, 28(4): 534-541.
[5]	Liu X, Yan K, Lin X, et al. The association between BRAFV600E mutation and pathological features in PTC [J]. Eur Arch Otorhinolaryngol, 2014, 271(11): 3041-3052.
[6]	Kim YS, Kim JS, Bae JS, et al. Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma [J]. World J Surg Oncol, 2013, 11: 99-99.
[7]	Gupta MK, Taguba L, Arciaga R, et al. Detection of circulating thyroid cancer cells by reverse transcription－PCR for thyroid－stimulating hormone receptor and thyroglobulin: The importance of primer selection. Clin Chem. 2002, 48:1862-1865.
[8]	Kinyas K, Onder S, Kosemehmetoglu K, et al. Methylation status of TSHr in well differentiated thyroid cancer by using cytologic material[J]. BMC Cancer, 2015, 15:824-824.
[9]	Khan MS, Pandith AA, Masoodi SR, et al. Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status[J]. Endocrine, 2014, 47(2):449-455.
[10]	Zheng H, Wang H, Jiang H, et al. BRAF－Activated Long Non－coding RNA Modulates Papillary Thyroid Carcinoma Cell Proliferation through Regulating Thyroid Stimulating Hormone Receptor[J]. Cancer Res Treat, 2016, 48(2):698-707.
[11]	郝少龙，马纪红，刘新承，等．外周血TSHR－mRNA检测在甲状腺乳头状癌中的临床意义[J/CD]．中华普外科手术学杂志(电子版)，2017，11(6):491-495.

基因型	阴性	弱阳性	阳性	强阳性	合计
BRAF基因突变型	2	26	36	8	72
BRAF基因野生型	1	10	24	15	50
合计	3	36	60	23	122
基因型	χ²值	df	P值	95% CI
BRAF基因突变型	8.277	3	0.032	0.027～0.036
BRAF基因野生型	8.277	3	0.032	0.027～0.036

基因型	阴性	弱阳性	阳性	强阳性	合计
BRAF基因突变型	2	26	36	8	72
BRAF基因野生型	1	10	24	15	50
合计	3	36	60	23	122
基因型	χ²值	df	P值	95% CI
BRAF基因突变型	8.277	3	0.032	0.027～0.036
BRAF基因野生型	8.277	3	0.032	0.027～0.036

[1]	Yonghao Li, Xuefei Gao, Tiantian Guo, Jin Zhang, Caizhen Zhang, Jing Liu. Advances in the research of mechanisms related to obesity combined with thyroid carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(04): 311-315.
[2]	Yao Chen, Boqun Xu, Zhihui Gao. Efficacy and safety of modified intermediate upper approach radical resection in the treatment of thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 619-622.
[3]	Zhanbin Cui, Junli Qiao, Lili Zhang, Mingqiang Han. Correlation between urinary iodine levels and stratified risk of recurrence in patients with papillary thyroid cancer after surgery [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 615-618.
[4]	Yutao Yuan, Jinlin Xing, Kefei Xie, Kai Yin. Correlation between CT findings and BRAF^V600E gene mutation and central lymph node metastasis in papillary thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 611-614.
[5]	Cheng Xu, Lulu Wang, Shaohua Wang. Application of eluent thyroglobulin in metastatic lymph nodes of thyroid papillary carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 701-704.
[6]	Lichao Fan, Jinying Guo, Xin Chen. The significance of detection of wild-type RET and RET/PTC fusion gene for lymph node dissection in the central region of papillary thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 631-635.
[7]	Hui Huang, Xinqiang Zhu. Efficacy and influencing factors of ¹³¹I in the treatment of differentiated thyroid carcinoma under 45 years old [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 627-630.
[8]	Zhenjian Jiang, Ming Jiang, Dali Huang. The expression and prognostic value of TK1 and Ki67 proteins in differentiated thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 623-626.
[9]	Yi Wang, Sizhe Xu, Zhangxia Ren. Effect of endoscopic unilateral thyroid lobectomy via thoracic breast approach and open surgery on postoperative recovery in patients with differentiated thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 542-545.
[10]	Rong Zhang, Hongzhen Qin, Xiaodong Yang, Shuang Liu, Mingfeng Liu, Xiutang Cao. Clinical application and observation of postoperative rehabilitation exercise of patients with differentiated thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 439-442.
[11]	Shanbin Guan, Tianbin Huang, Changquan Wang, Liushan Lu. Clinical effect of oral vestibular approach for thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 192-196.
[12]	Daliu Chen, Yonggang Song, Haijian Zhao, Xiaoyu Zhang. Clinical effect evaluation of three different approaches in endoscopic radical thyroidectomy for thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 188-191.
[13]	Jiandong Li, Zhuoliang Li, Tao Yin. Clinical study of lymph node metastasis of posterior jugular vein group in papillary thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 184-187.
[14]	Juan Yan, Hao Shi, Yu Zhang, Jie Zhang, Mingxiang Tuo, Qing Tian, Zhiping Xu, Xiapeng Xiao. Comparative study of different parathyroid identification schemes during secondary operation for recurrent thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 180-183.
[15]	Min Yang, Ting Zhang, Ling Zhong, Junlan Liu, Junze Du, Xiang Cui, Ye Zhang, Linjun Fan. A comparative study of traditional endoscopic surgery and Da Vinci robotic surgery for low-risk thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 176-179.

Please choose a citation manager

Content to export

Clinical investigation of the expression of TSHR and BRAFV600E gene mutation in papillary thyroid carcinoma

RichHTML

PDF (PC)

Knowledge